Abstracts

296 – Antigen-Specific Memory B Cells of Extrafollicular Origin May Contribute to ART-Free HIV Control

Background T cell-dependent antigens drive two distinct class-switched B cell responses, extrafollicular and germinal center reactions, that can both give rise to durable memory B cell populations. While an atypical B cell population, resembling transient activated B cells, has been reported in peripheral blood samples from persons living with HIV (PLWH), the functional contribution of these…

361 – Longitudinal Dynamics of Polyadenylated HIV Transcripts During Treatment Interruption

Background Individuals living with HIV require antiretroviral therapy (ART) to suppress viral replication. When therapy is stopped, most experience virologic rebound, but the interval between cessation and rebound varies widely, and the events preceding rebound are poorly understood. We examined how levels of polyadenylated (poly-A) HIV transcripts change during analytic treatment interruption (ATI), hypothesizing that…

916 – Trends in Homelessness and Unstable Housing Among Adults With HIV in the CNICS Cohort

Background People with HIV (PWH) disproportionately experience homelessness and unstable housing (HUH), which is associated with difficulties accessing care and worse clinical outcomes. Limited data are available on how housing status among PWH varies by location or over time.  Methods We used data from the Center for AIDS Research Network of Integrated Clinic Systems (CNICS),…

751 – Cognitive and Neuropsychiatric Impairments Associated With COVID-19 in Patients Evaluated in Brazil

Background Neurological and neuropsychiatric impairments after covid-19 have been described since the beginning of the pandemic, particularly cognitive impairment, referred to as brain fog, and deficits in attention, executive function, language, processing speed, and memory are the most common symptoms. Our objective is to evaluate cognitive and neuropsychiatric impairments in patients who presented neurological manifestations associated…

428 – Safety and Viral Kinetics of Analytical Treatment Interruption in PWH in a Large Phase II Global RCT

Background Viral suppression without continuous antiretroviral therapy (ART) is an unmet need among people with HIV (PWH), and analytical treatment interruption (ATI) is used for evaluating potential therapies for long-term virologic control without lifelong ART. This phase 2 trial evaluated the safety and efficacy of budigalimab ± trosunilimab to maintain suppression in PWH undergoing ATI. Here, we describe…

852 – Efficacy and Safety of B/F/TAF in Children and Infants Aged ≥1 Month, Weighing 3 to <25 kg: Week 24

Background Treatment options for children with HIV are limited. Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is a well-tolerated antiretroviral therapy (ART) with a high barrier to resistance approved in the US for children weighing ≥14 kg and in other countries for children ≥25 kg. However, data on its use in younger children are limited. We present efficacy and safety outcomes for…